298 related articles for article (PubMed ID: 29670624)
1. Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination.
Haug M; Brede G; Håkerud M; Nedberg AG; Gederaas OA; Flo TH; Edwards VT; Selbo PK; Høgset A; Halaas Ø
Front Immunol; 2018; 9():650. PubMed ID: 29670624
[TBL] [Abstract][Full Text] [Related]
2. Combined Photosensitization and Vaccination Enable CD8 T-Cell Immunity and Tumor Suppression Independent of CD4 T-Cell Help.
Varypataki EM; Hasler F; Waeckerle-Men Y; Vogel-Kindgen S; Høgset A; Kündig TM; Gander B; Halin C; Johansen P
Front Immunol; 2019; 10():1548. PubMed ID: 31333674
[TBL] [Abstract][Full Text] [Related]
3. Photochemically-Mediated Inflammation and Cross-Presentation of
Waeckerle-Men Y; Kotkowska ZK; Bono G; Duda A; Kolm I; Varypataki EM; Amstutz B; Meuli M; Høgset A; Kündig TM; Halin C; Sander P; Johansen P
Front Immunol; 2022; 13():815609. PubMed ID: 35173729
[TBL] [Abstract][Full Text] [Related]
4. Photochemical Internalization Enhanced Vaccination Is Safe, and Gives Promising Cellular Immune Responses to an HPV Peptide-Based Vaccine in a Phase I Clinical Study in Healthy Volunteers.
Otterhaug T; Janetzki S; Welters MJP; Håkerud M; Nedberg AG; Edwards VT; Boekestijn S; Loof NM; Selbo PK; Olivecrona H; van der Burg SH; Høgset A
Front Immunol; 2020; 11():576756. PubMed ID: 33488576
[TBL] [Abstract][Full Text] [Related]
5. Intradermal photosensitisation facilitates stimulation of MHC class-I restricted CD8 T-cell responses of co-administered antigen.
Håkerud M; Waeckerle-Men Y; Selbo PK; Kündig TM; Høgset A; Johansen P
J Control Release; 2014 Jan; 174():143-50. PubMed ID: 24280261
[TBL] [Abstract][Full Text] [Related]
6. Cytosolic Delivery of Liposomal Vaccines by Means of the Concomitant Photosensitization of Phagosomes.
Hjálmsdóttir Á; Bühler C; Vonwil V; Roveri M; Håkerud M; Wäckerle-Men Y; Gander B; Johansen P
Mol Pharm; 2016 Feb; 13(2):320-9. PubMed ID: 26704885
[TBL] [Abstract][Full Text] [Related]
7. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.
Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K
J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727
[TBL] [Abstract][Full Text] [Related]
8. Photochemical targeting of antigens to the cytosol for stimulation of MHC class-I-restricted T-cell responses.
Waeckerle-Men Y; Mauracher A; Håkerud M; Mohanan D; Kündig TM; Høgset A; Johansen P
Eur J Pharm Biopharm; 2013 Sep; 85(1):34-41. PubMed ID: 23461859
[TBL] [Abstract][Full Text] [Related]
9. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy.
Ma W; Smith T; Bogin V; Zhang Y; Ozkan C; Ozkan M; Hayden M; Schroter S; Carrier E; Messmer D; Kumar V; Minev B
J Transl Med; 2011 Mar; 9():34. PubMed ID: 21450109
[TBL] [Abstract][Full Text] [Related]
10. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
11. Processing and presentation of tumor antigens and vaccination strategies.
van der Bruggen P; Van den Eynde BJ
Curr Opin Immunol; 2006 Feb; 18(1):98-104. PubMed ID: 16343880
[TBL] [Abstract][Full Text] [Related]
12. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
[TBL] [Abstract][Full Text] [Related]
13. Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.
Chiang CY; Chen YJ; Wu CC; Liu SJ; Leng CH; Chen HW
Front Immunol; 2018; 9():822. PubMed ID: 29755461
[TBL] [Abstract][Full Text] [Related]
14. Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.
Harao M; Mittendorf EA; Radvanyi LG
BioDrugs; 2015 Feb; 29(1):15-30. PubMed ID: 25523015
[TBL] [Abstract][Full Text] [Related]
15. Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes.
Oizumi S; Strbo N; Pahwa S; Deyev V; Podack ER
J Immunol; 2007 Aug; 179(4):2310-7. PubMed ID: 17675492
[TBL] [Abstract][Full Text] [Related]
16. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
17. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.
Varypataki EM; van der Maaden K; Bouwstra J; Ossendorp F; Jiskoot W
AAPS J; 2015 Jan; 17(1):216-26. PubMed ID: 25387996
[TBL] [Abstract][Full Text] [Related]
18. Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes.
Shen X; Wong SB; Buck CB; Zhang J; Siliciano RF
J Immunol; 2002 Oct; 169(8):4222-9. PubMed ID: 12370352
[TBL] [Abstract][Full Text] [Related]
19. Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide.
Ikeuchi N; Futami J; Hosoi A; Noji S; Kurachi M; Ueha S; Fujii S; Yamada H; Matsushima K; Moriyasu F; Kakimi K
Biochem Biophys Res Commun; 2010 Feb; 392(2):217-22. PubMed ID: 20067764
[TBL] [Abstract][Full Text] [Related]
20. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
